Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Gains of EPOR and ERG genes in adult erythroleukaemia.

Adélaïde J, Cervera N, Guille A, Murati A, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Gelsi-Boyer V.

Br J Haematol. 2020 Mar 29. doi: 10.1111/bjh.16586. [Epub ahead of print] No abstract available.

PMID:
32227335
2.

Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias.

Cervera N, Lhoumeau AC, Adélaïde J, Guille A, Murati A, Mozziconacci MJ, Vey N, Birnbaum D, Gelsi-Boyer V.

Haematologica. 2019 Oct 10. pii: haematol.2019.231142. doi: 10.3324/haematol.2019.231142. [Epub ahead of print]

3.

Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification.

Cervera N, Carbuccia N, Mozziconacci MJ, Adélaïde J, Garnier S, Guille A, Murati A, Chaffanet M, Vey N, Birnbaum D, Gelsi-Boyer V.

Blood Cancer J. 2017 Aug 25;7(8):e594. doi: 10.1038/bcj.2017.68. No abstract available.

4.

Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.

Courtier F, Carbuccia N, Garnier S, Guille A, Adélaïde J, Cervera N, Gelsi-Boyer V, Mozziconacci MJ, Rey J, Vey N, Chaffanet M, Birnbaum D, Murati A.

Haematologica. 2017 Jan;102(1):e11-e14. doi: 10.3324/haematol.2016.152363. Epub 2016 Oct 14. No abstract available.

5.

Epigenetically centered evolution in an example of myeloid malignancy.

Adélaide J, Cervera N, Carbuccia N, Garnier S, Guille A, Mozziconnaci MJ, Devillier R, Chaffanet M, Vey N, Birnbaum D, Gelsi-Boyer V.

Am J Hematol. 2016 Sep;91(9):E361-2. doi: 10.1002/ajh.24450. Epub 2016 Jul 4. No abstract available.

6.

Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing.

Cervera N, Carbuccia N, Garnier S, Guille A, Adélaïde J, Murati A, Vey N, Mozziconacci MJ, Chaffanet M, Birnbaum D, Gelsi-Boyer V.

Leukemia. 2016 Apr;30(4):966-70. doi: 10.1038/leu.2015.198. Epub 2015 Jul 23. No abstract available.

PMID:
26202927
7.

Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML).

Coppin E, Gelsi-Boyer V, Morelli X, Cervera N, Murati A, Pandolfi PP, Birnbaum D, Nunès JA.

Leukemia. 2015 Feb;29(2):500-2. doi: 10.1038/leu.2014.288. Epub 2014 Sep 25. No abstract available.

8.

Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.

Cervera N, Itzykson R, Coppin E, Prebet T, Murati A, Legall S, Vey N, Solary E, Birnbaum D, Gelsi-Boyer V.

Am J Hematol. 2014 Jun;89(6):604-9. doi: 10.1002/ajh.23702. Epub 2014 Apr 10.

9.

Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Gelsi-Boyer V, Cervera N, Bertucci F, Brecqueville M, Finetti P, Murati A, Arnoulet C, Mozziconacci MJ, Mills KI, Cross NC, Vey N, Birnbaum D.

Haematologica. 2013 Apr;98(4):576-83. doi: 10.3324/haematol.2012.071506. Epub 2012 Oct 12.

10.

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms.

Brecqueville M, Cervera N, Adélaïde J, Rey J, Carbuccia N, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Gelsi-Boyer V, Murati A.

Blood Cancer J. 2011 Aug;1(8):e33. doi: 10.1038/bcj.2011.31. Epub 2011 Aug 26. No abstract available.

11.

Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target.

Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera N, Josselin E, Finetti P, Guille A, Larderet G, Viens P, Sebti S, Bertucci F, Birnbaum D, Charafe-Jauffret E.

Stem Cells. 2012 Jul;30(7):1327-37. doi: 10.1002/stem.1122.

12.

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A.

Genes Chromosomes Cancer. 2012 Aug;51(8):743-55. doi: 10.1002/gcc.21960. Epub 2012 Apr 9.

PMID:
22489043
13.

Kinome expression profiling and prognosis of basal breast cancers.

Sabatier R, Finetti P, Mamessier E, Raynaud S, Cervera N, Lambaudie E, Jacquemier J, Viens P, Birnbaum D, Bertucci F.

Mol Cancer. 2011 Jul 21;10:86. doi: 10.1186/1476-4598-10-86.

14.

Gene expression profiling and its utility in prediction of local relapse after breast-conserving therapy in early breast cancer.

Sabatier R, Finetti P, Cervera N, Tallet A, Benchalal M, Houvenaeghel G, Jacquemier J, Birnbaum D, Bertucci F.

Cancer Genomics Proteomics. 2011 Jul-Aug;8(4):199-209.

PMID:
21737613
15.

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes.

Brecqueville M, Cervera N, Gelsi-Boyer V, Murati A, Adélaïde J, Chaffanet M, Rey J, Vey N, Mozziconacci MJ, Birnbaum D.

Blood Cancer J. 2011 May;1(5):e18. doi: 10.1038/bcj.2011.15. Epub 2011 May 13. No abstract available.

16.

Loss, mutation and deregulation of L3MBTL4 in breast cancers.

Addou-Klouche L, Adélaïde J, Finetti P, Cervera N, Ferrari A, Bekhouche I, Sircoulomb F, Sotiriou C, Viens P, Moulessehoul S, Bertucci F, Birnbaum D, Chaffanet M.

Mol Cancer. 2010 Aug 10;9:213. doi: 10.1186/1476-4598-9-213.

17.

[DNA microarrays and prediction of clinical outcome in ovarian carcinoma patients].

Sabatier R, Finetti P, Cervera N, Birnbaum D, Bertucci F.

Bull Cancer. 2010 Aug;97(8):979-89. doi: 10.1684/bdc.2010.1162. Review. French.

18.

A gene expression signature identifies two prognostic subgroups of basal breast cancer.

Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra JM, Jacquemier J, Viens P, Birnbaum D, Bertucci F.

Breast Cancer Res Treat. 2011 Apr;126(2):407-20. doi: 10.1007/s10549-010-0897-9. Epub 2010 May 21.

19.

Retinoid signaling regulates breast cancer stem cell differentiation.

Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, Wicha MS, Birnbaum D, Charafe-Jauffret E.

Cell Cycle. 2009 Oct 15;8(20):3297-302. Epub 2009 Oct 10.

20.

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Gelsi-Boyer V, Trouplin V, Adélaïde J, Bonansea J, Cervera N, Carbuccia N, Lagarde A, Prebet T, Nezri M, Sainty D, Olschwang S, Xerri L, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D.

Br J Haematol. 2009 Jun;145(6):788-800. doi: 10.1111/j.1365-2141.2009.07697.x. Epub 2009 Apr 15.

PMID:
19388938
21.

Gene expression profiling and prediction of clinical outcome in ovarian cancer.

Sabatier R, Finetti P, Cervera N, Birnbaum D, Bertucci F.

Crit Rev Oncol Hematol. 2009 Nov;72(2):98-109. doi: 10.1016/j.critrevonc.2009.01.007. Epub 2009 Feb 26. Review.

PMID:
19249225
22.

Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.

Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS.

Cancer Res. 2009 Feb 15;69(4):1302-13. doi: 10.1158/0008-5472.CAN-08-2741. Epub 2009 Feb 3.

23.

How different are luminal A and basal breast cancers?

Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, Chaffanet M, Maraninchi D, Viens P, Birnbaum D.

Int J Cancer. 2009 Mar 15;124(6):1338-48. doi: 10.1002/ijc.24055.

24.

Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases.

Murati A, Gervais C, Carbuccia N, Finetti P, Cervera N, Adélaïde J, Struski S, Lippert E, Mugneret F, Tigaud I, Penther D, Bastard C, Poppe B, Speleman F, Baranger L, Luquet I, Cornillet-Lefebvre P, Nadal N, Nguyen-Khac F, Pérot C, Olschwang S, Bertucci F, Chaffanet M, Lessard M, Mozziconacci MJ, Birnbaum D; Groupe Francophone de Cytogénétique Hématologique.

Leukemia. 2009 Jan;23(1):85-94. doi: 10.1038/leu.2008.257. Epub 2008 Sep 25.

PMID:
18818702
25.

[Prognostic classification of breast cancer and gene expression profiling].

Bertucci F, Finetti P, Cervera N, Birnbaum D.

Med Sci (Paris). 2008 Jun-Jul;24(6-7):599-606. doi: 10.1051/medsci/20082467599. Review. French.

26.

How basal are triple-negative breast cancers?

Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D.

Int J Cancer. 2008 Jul 1;123(1):236-40. doi: 10.1002/ijc.23518.

27.

Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.

Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M, Jacquemier J, Viens P, Birnbaum D, Bertucci F.

Cancer Res. 2008 Feb 1;68(3):767-76. doi: 10.1158/0008-5472.CAN-07-5516.

28.

Integrated profiling of basal and luminal breast cancers.

Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M.

Cancer Res. 2007 Dec 15;67(24):11565-75.

29.

Moesin expression is a marker of basal breast carcinomas.

Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, Cervera N, Geneix J, Hassanein M, Rabayrol L, Sobol H, Taranger-Charpin C, Xerri L, Viens P, Birnbaum D, Jacquemier J.

Int J Cancer. 2007 Oct 15;121(8):1779-85.

30.

Gene expression profiling separates chronic myelomonocytic leukemia in two molecular subtypes.

Gelsi-Boyer V, Cervera N, Bertucci F, Trouplin V, Remy V, Olschwang S, Chaffanet M, Vey N, Mozziconacci MJ, Birnbaum D.

Leukemia. 2007 Nov;21(11):2359-62. Epub 2007 Jun 14. No abstract available.

PMID:
17568812
31.

A gene signature in breast cancer.

Bertucci F, Cervera N, Birnbaum D.

N Engl J Med. 2007 May 3;356(18):1887-8; author reply 1887-8. No abstract available.

PMID:
17476019
32.

Gene expression profiling and clinical outcome in breast cancer.

Bertucci F, Finetti P, Cervera N, Maraninchi D, Viens P, Birnbaum D.

OMICS. 2006 Winter;10(4):429-43. Review.

PMID:
17233555
33.

Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q.

Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Rougé C, Ursule L, Nguyen C, Bibeau F, Rodriguez C, Theillet C.

Br J Cancer. 2006 Nov 20;95(10):1439-47. Epub 2006 Oct 24.

34.

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.

Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Chaffanet M.

BMC Cancer. 2006 Oct 13;6:245.

35.

Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators.

Lelièvre H, Cervera N, Finetti P, Delhommeau F, Vainchenker W, Bertucci F, Birnbaum D.

Leukemia. 2006 Oct;20(10):1885-8. Epub 2006 Aug 10. No abstract available.

PMID:
16900207
36.

Prognosis and gene expression profiling of 20q13-amplified breast cancers.

Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adélaïde J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, Chaffanet M, Birnbaum D, Bertucci F.

Clin Cancer Res. 2006 Aug 1;12(15):4533-44.

37.

Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.

Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adélaïde J, Debono S, Houvenaeghel G, Maraninchi D, Viens P, Charpin C, Jacquemier J, Birnbaum D.

Cancer Res. 2006 May 1;66(9):4636-44.

38.

Comprehensive profiling of 8p11-12 amplification in breast cancer.

Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rougé C, Lasorsa L, Letessier A, Ginestier C, Monville F, Esteyriès S, Adélaïde J, Esterni B, Henry C, Ethier SP, Bibeau F, Mozziconacci MJ, Charafe-Jauffret E, Jacquemier J, Bertucci F, Birnbaum D, Theillet C, Chaffanet M.

Mol Cancer Res. 2005 Dec;3(12):655-67.

39.

Gene expression profiling of breast cell lines identifies potential new basal markers.

Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F.

Oncogene. 2006 Apr 6;25(15):2273-84.

PMID:
16288205
40.

ETV6 gene rearrangements in invasive breast carcinoma.

Letessier A, Ginestier C, Charafe-Jauffret E, Cervera N, Adélaïde J, Gelsi-Boyer V, Ahomadegbe JC, Benard J, Jacquemier J, Birnbaum D, Chaffanet M.

Genes Chromosomes Cancer. 2005 Sep;44(1):103-8.

PMID:
15887243
41.

Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.

Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, Nguyen C, Xerri L, Houlgatte R, Jacquemier J, Viens P, Birnbaum D.

Cancer Res. 2005 Mar 15;65(6):2170-8.

42.

Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes.

Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Ursule L, Nguyen C, Redon R, du Manoir S, Rodriguez C, Theillet C.

Cancer Res. 2004 Sep 15;64(18):6453-60.

43.

Family change during an unwed teenage pregnancy.

Cervera N.

J Youth Adolesc. 1994 Feb;23(1):119-40.

PMID:
12287750
44.
45.

Incarceration, coping, and support.

Carlson BE, Cervera NJ.

Soc Work. 1991 Jul;36(4):279-85.

PMID:
1896887
46.

[AMBULATORY TREATMENT OF NON-TREATED TUBERCULOSIS PATIENTS. PRELIMINARY REPORT].

SENTIES R, CERVERA N, CASTILLONAVA J.

Neumol Cir Torax. 1964 Jan-Feb;25:21-5. Spanish. No abstract available.

PMID:
14115176
47.

[Tuberculin investigation of patients with active tuberculosis].

SENTIES R, MOLAS F, CERVERA N.

Salud Publica Mex. 1962 Jan-Feb;4:103-8. Spanish. No abstract available.

PMID:
13910704

Supplemental Content

Loading ...
Support Center